Duke University Medical Center
Durham, North Carolina, 27706, United States
NCT Number: NCT02869451
The purpose of this pilot project is to pilot-test a combined cannabis and smoking cessation treatment. The intervention combines mobile technology with behavioral strategies, counseling, and medications.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Durham, North Carolina, 27706, United States
Cannabis is the most widely used illicit drug in the United States with 19.8 million current users. Population based data indicate that almost all cannabis users (90%) have a lifetime history of tobacco smoking and the majority (74%) currently smoke tobacco. While cannabis use alone is associated with significant adverse health effects, tobacco smoking is the number one preventable cause of illness and death in the U.S. This is true even among those using illicit drugs where the tobacco -related mortality rate is twice that of the general population. Among cannabis users, smoking tobacco is associated with increased frequency of marijuana use, increased morbidity, and poorer cannabis cessation outcomes. There is strong evidence for the short -term efficacy for cannabis use disorder (CUD) and smoking of contingency management (CM). It is an intensive behavioral therapy that provides incentives (vouchers, money) to individuals misusing substances contingent upon objective evidence from drug use. Implementation of CM has been limited because of the need to verify abstinence multiple times daily using clinic based monitoring and effects are short lived. The investigators recently developed a smart -phone application which allows a patient to video themselves several times daily while using a small CO monitor and to transmit the data to a secure server which has made the use of CM for outpatient smoking cessation portable and feasible. The mobile CM (mCM) approach paired with cognitive-behavioral counseling and pharmacological smoking cessation aids has been effective in reducing smoking in the short and long-term. The purpose of this pilot project is to pilot-test a combined cannabis and smoking mCM intervention. The pilot will allow the investigators to examine feasibility of the treatment and of planned recruitment strategies. These project aims will provide the first step toward implementation of an innovative approach that builds upon the power of mHealth technology to reduce the prevalence of both CUD and cigarette smoking.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Prescribed one week prior to quit and continued until the 6 month follow-up visit.
Other names: Zyban
Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
Initiated at smoking quit date.
Other names: nicotine gum; nicorette
Initiated at smoking quit date.
5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
treatment that provides money rewards for abstinence from smoking and marijuana
Time frame: 6 month follow up
Participants self-report smoking behavior since smoking quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial smoking quit date.
Time frame: 6 month follow up
Self-reported abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.
Time frame: 6 month follow up
Participants self-report marijuana use since marijuana quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial quit date.
Time frame: 6 month follow up
Self-reported abstinence (primary outcome) will be verified by oral fluid (OF) cannabis assessment. Oral fluid samples will be collected from participants who self-report prolonged abstinence.
Time frame: 6 month follow up
7-day point prevalence abstinence is defined as no smoking in the prior 7 days.
Time frame: 6 month follow up
7-day point prevalence abstinence is defined as no marijuana use in the prior 7 days.
Time frame: 6 month follow up
30-day point prevalence abstinence is defined as no marijuana use in the prior 30 days.
Time frame: 6 month follow up
30-day point prevalence abstinence is defined as no smoking in the prior 30 days.
Time frame: 3 month follow up
7-day point prevalence abstinence is defined as no smoking in the prior 7 days.
Time frame: 3 month follow up
7-day point prevalence abstinence is defined as no marijuana use in the prior 7 days.
Time frame: 3 month follow up
Self-reported abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.
Time frame: 3 month follow up
Self-reported abstinence (primary outcome) will be verified by oral fluid (OF) cannabis assessment. Oral fluid samples will be collected from participants who self-report prolonged abstinence.
Time frame: baseline, 6 month follow up
Participants will self-report amount of marijuana used in past week; this will be compared to self-reported amount smoked per week prior to quit date.
Time frame: 30 days prior to quit date, 6 month follow up
Participants will self-report number of days marijuana used in the past 30 days and this will be compared for the entire group to self-reported number of days of use in 30 days prior to quit. The proportion will be calculated by totaling baseline days used and pretreatment days used, and then dividing baseline days used by pretreatment days used.
Time frame: 7 days prior to quit date, 6 month follow up
Self-reported number of cigarettes smoked each day in past 7 days; this will be compared to self-reported amount smoked in week prior to quit date
Time frame: 30 days prior to quit date, 6 month follow up
Participants will self-report number of days smoked in the past 30 days and this will be compared (for the entire group) to self-reported number of days smoked in 30 days prior to quit. The proportion will be calculated by totaling baseline days used and pretreatment days used, and then dividing baseline days used by pretreatment days used.
Time frame: 3 month follow up
Participants upload video recordings of abstinence verification as part of contingency management treatment. Percentage of missed videos (compared to expected videos) will be assessed as a measure of feasibility of the contingency management intervention
Time frame: 3 month follow up
Participants attend telephone counseling sessions. Number of missed sessions for the total group will be assessed as a measure of acceptability of the behavioral counseling
Time frame: Evaluated at 6 month follow-up
The number of participants who withdraw from the study will be evaluated as a measure of treatment feasibility and acceptability
Duke University
Other
Mobile Contingency Management for Concurrent Abstinence From Cannabis and Cigarette Smoking: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04429568
Behavior, Blood Coagulation Disorders
San Francisco, California, United States
View Trial DetailsNCT04284813
Alcohol, Alcohol Use Disorder
Belmont, Massachusetts, United States
View Trial DetailsNCT01081119
Alcohol Drinking, Behavior
Los Angeles, California, United States
View Trial DetailsNCT06609083
Behavior, Cannabis Use
Baltimore, Maryland, United States
View Trial Details